Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the re-investment of dividends paid on January 10, 2008. The transaction price was GBP 13.89 per ordinary share. The specific increases were:
- Mr J S Heslop: 295 shares
- Mrs P A Heslop: 71 shares
- Mr R Bondy: 318 shares
- Mr D Learmouth: 69 shares
- Dr D Pulman: 132 shares
- Mrs C R Pulman: 44 shares
- Mr A P Witty: 22 shares
- Mrs C M Witty: 292 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 10, 2008 (dividend reinvestment); Notification Date: January 11, 2008.
- Share Price: GBP 13.89 per ordinary share.
- Participants: Eight individuals, including directors and connected persons (e.g., Mr A P Witty, Mr J S Heslop).
- Regulatory Basis: Filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.